197.14 USD
-0.25 (-0.13%)
197.14 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 85% to LGND. The Buy consensus is the weighted average rating of the current analysts ratings.
LGND was analyzed by 13 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about LGND.
In the previous month the buy percentage consensus was at a similar level.
LGND was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-10 | Stifel | Maintains | Buy -> Buy |
| 2025-12-09 | Citigroup | Initiate | Buy |
| 2025-11-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-07 | Benchmark | Maintains | Buy -> Buy |
| 2025-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-02 | Benchmark | Maintains | Buy -> Buy |
| 2025-08-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-30 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-04-10 | Stifel | Initiate | Buy |
| 2024-12-23 | Benchmark | Reiterate | Buy -> Buy |
| 2024-12-16 | Barclays | Maintains | Overweight -> Overweight |
| 2024-12-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-08 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-11-08 | Benchmark | Maintains | Buy -> Buy |
| 2024-11-08 | Barclays | Maintains | Overweight -> Overweight |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-28 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-03 | Oppenheimer | Initiate | Outperform |
| 2024-08-12 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-12 | Benchmark | Maintains | Buy -> Buy |
| 2024-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
LIGAND PHARMACEUTICALS / LGND FAQ
What is the consensus rating for LIGAND PHARMACEUTICALS (LGND) stock?
The consensus rating for LIGAND PHARMACEUTICALS (LGND) is 84.6154 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover LIGAND PHARMACEUTICALS (LGND) stock?
The number of analysts covering LIGAND PHARMACEUTICALS (LGND) is 13.